Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that
Read More
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regulatory approvals, this could eventually be used as a treatment for clients in psychedelic-assisted therapy. Numinus strives to be at the cutting edge of psychedelic-assisted therapies
atai has administered the first dosage of their VLS-01 synthetic DMT drug
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)
Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel
Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for
atai has administered the first dosage of their VLS-01 synthetic DMT drug in their Phase 1 single-ascending dose (SAD) trial, with topline
Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) filed for two new provisional patents strengthening the company’s intellectual
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30
Revitalist Lifestyle and Wellness LTD. (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) recently announced a new joint venture partnership with Wake Network, Inc.
Psychedelic biotechnology company Bright Minds Biosciences recently announced that it has dosed the first patient in a Phase I trial (NCT 05397041)
Drug discovery and development company Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) announced today the company has identified three additional families
Psychedelic biopharmaceutical company Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) announced today the dosing of the first two patients in the company’s Phase
One of the largest publicly listed ketamine focused clinic operations operating in the United States, Revitalist Lifestyle and Wellness Ltd. (CSE: CALM)
